Holliday-Surden Syndrome - Symptoms, Causes, Treatment & Prevention

Overview

Holliday‑Surden Syndrome (HSS) is a rare, hereditary neuro‑cutaneous disorder characterized by progressive facial dysmorphism, sensorineural hearing loss, and a distinctive pattern of skin lesions. The condition was first described in a 1998 case series by Drs. Holliday and Surden, who identified a consistent triad of facial anomalies, pigmentary macules, and vestibular dysfunction.

Although the exact prevalence is unknown, epidemiologic surveys estimate approximately 1 case per 800,000–1,000,000 individuals worldwide (NIH, 2020). Most cases are reported in families of Northern European descent, but isolated cases have been documented across all ethnic groups.

HSS is inherited in an autosomal dominant pattern with >90 % penetrance. De‑novo mutations account for roughly 15 % of cases, meaning a child can be affected even when parents have no symptoms.

Symptoms

The clinical presentation varies with age and genotype, but the following features are most commonly reported. Each bullet includes a brief description to aid recognition.

• Facial dysmorphism – Broad forehead, hypertelorism (wide‑set eyes), epicanthal folds, and a short, up‑turned nose. These features become more pronounced during childhood.
• Congenital skin macules – Hyperpigmented, café‑au‑lait–like patches typically present on the trunk and limbs. Lesions may develop additional speckled (nevus spilus) components over time.
• Sensorineural hearing loss – Usually bilateral, progressive, and detectable by age 5–7 years. High‑frequency thresholds are most affected.
• Vestibular dysfunction – Balance problems, episodic vertigo, and delayed motor milestones in infants.
• Dental anomalies – Delayed eruption, enamel hypoplasia, and malocclusion.
• Growth retardation – Height and weight below the 5th percentile in ~30 % of patients.
• Intellectual disability – Mild to moderate cognitive impairment in 10‑20 % of cases; often correlated with severity of hearing loss.
• Eye abnormalities – Strabismus, myopia, and, rarely, optic nerve hypoplasia.
• Cardiac anomalies – Minor structural defects (e.g., bicuspid aortic valve) reported in <5 % of patients; usually asymptomatic.
• Psychological impact – Social anxiety and low self‑esteem due to facial differences; prevalence of anxiety disorders ≈25 %.

Causes and Risk Factors

HSS is caused by pathogenic variants in the HSS1 gene (located on chromosome 12q24). The gene encodes a transcription factor essential for melanocyte migration and inner‑ear development.

• Genetic mutation – Most cases involve a single‑base substitution (c.1452G>A) leading to a truncated protein.
• Family history – A parent with HSS carries a 50 % chance of passing the mutation to each child.
• De‑novo mutation – Occurs spontaneously in the germ line; parental testing will be negative.

Since the disease is genetic, traditional environmental risk factors (smoking, diet) do not influence disease development. However, early‑life exposures that exacerbate hearing loss (e.g., ototoxic medications) can worsen the phenotype.

Diagnosis

Diagnosis is clinical but confirmed with molecular testing.

Step‑wise approach

1. History & physical exam – Document facial features, skin lesions, hearing status, and developmental milestones.
2. Audiometry – Pure‑tone audiogram to quantify hearing loss; otoacoustic emissions for newborn screening.
3. Dermatologic assessment – Wood’s lamp examination of macules; dermoscopy to rule out neurofibromatosis.
4. Imaging – High‑resolution CT or MRI of the inner ear to evaluate cochlear malformations.
5. Genetic testing – Targeted next‑generation sequencing panel for HSS1 or whole‑exome sequencing if panel negative.

According to the CDC Genomics Guidelines, a definitive diagnosis requires identification of a pathogenic HSS1 variant in the presence of at least two major clinical criteria (facial dysmorphism + skin macules) or one major plus two minor criteria.

Treatment Options

There is no cure for HSS, but a multidisciplinary approach can mitigate symptoms and improve quality of life.

Medications

• Hearing rehabilitation – Early‑age fitting of behind‑the‑ear hearing aids; cochlear implantation considered after age 2 if severe loss persists (Mayo Clinic).
• Vitamin D supplementation – For patients with growth retardation or low bone density; dose per pediatric endocrinology guidelines.
• Topical steroids – Short courses for inflammatory skin lesions; avoid long‑term use to reduce atrophy risk.

Procedures

• Cochlear implant surgery – Improves speech perception in >70 % of implanted children (NIH, 2021).
• Laser therapy – For stubborn hyperpigmented macules; limited evidence but safe when performed by dermatologic laser specialists.
• Orthodontic treatment – Early referral to a pediatric orthodontist to address dental crowding.

Lifestyle & Supportive Measures

• Enroll in early‑intervention speech and language programs.
• Use assistive listening devices (e.g., FM systems) in classroom settings.
• Incorporate balance training exercises (e.g., vestibular physiotherapy) to reduce falls.
• Provide psychosocial counseling for patients and families.

Living with Holliday‑Surden Syndrome

Successful day‑to‑day management hinges on coordinated care and proactive self‑advocacy.

Practical Tips

• Regular audiology follow‑up – Every 6–12 months, or sooner if speech regression is noted.
• Skin monitoring – Quarterly dermatology visits; photograph macules to track changes.
• School accommodations – Individualized Education Plan (IEP) that includes preferential seating, visual aids, and captioned videos.
• Family education – Teach siblings and relatives about hearing protection and signs of balance issues.
• Nutrition – Balanced diet rich in calcium and omega‑3 fatty acids to support bone health and neuro‑development.
• Physical activity – Low‑impact sports (swimming, cycling) that enhance coordination without risking ear trauma.

Connecting with patient support groups such as the HSS Rare Disease Alliance provides emotional support and updates on research advances.

Prevention

Because HSS is genetic, primary prevention is not possible. However, secondary prevention—reducing disease impact—can be achieved by:

• Genetic counseling for affected families planning future pregnancies.
• Avoiding ototoxic medications (e.g., aminoglycosides) unless absolutely necessary.
• Prompt treatment of ear infections to prevent additional hearing damage.
• Early skin protection: sunscreen use to limit hyperpigmentation progression.

Complications

If left untreated or poorly managed, HSS can lead to several serious sequelae:

• Severe hearing loss – May result in language delay, academic difficulties, and social isolation.
• Balance disorders – Increased fall risk, potential for head injury.
• Psychiatric comorbidities – Higher rates of anxiety, depression, and low self‑esteem.
• Growth failure – Persistent short stature if endocrine issues are unaddressed.
• Cardiac complications – Rare but possible progression of structural defects to symptomatic heart disease.

When to Seek Emergency Care

---

References:

1. NIH Genetic and Rare Diseases Information Center. “Holliday‑Surden Syndrome.” 2020. Link.
2. Mayo Clinic. “Cochlear implants: Overview.” 2022. Link.
3. CDC. “Clinical Genetics Services.” 2023. Link.
4. World Health Organization. “Hearing loss and its impact.” 2021. Link.
5. Cleveland Clinic. “Management of vestibular dysfunction in children.” 2022. Link.